Oncocyte Reports Full Year 2023 Financial Results
April 12, 2024 06:00 ET
|
OncoCyte Corporation
ONCOCYTE REPORTS FULL YEAR 2023 FINANCIAL RESULTS
Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
April 11, 2024 21:46 ET
|
OncoCyte Corporation
Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay
April 11, 2024 17:30 ET
|
OncoCyte Corporation
Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay
Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results
April 09, 2024 16:05 ET
|
OncoCyte Corporation
ONCOCYTE TO ANNOUNCE FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS
Oncocyte to Present at the Sequire Investor Summit in Puerto Rico
January 16, 2024 08:00 ET
|
OncoCyte Corporation
Oncocyte to Present at the Sequire Investor Summit in Puerto Rico
Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays
December 06, 2023 08:00 ET
|
OncoCyte Corporation
- Significant unmet need for regulated product in $2B US testing market - Opportunity for expedited pathway for kitted product in development IRVINE, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) --...
Oncocyte Reports Third Quarter 2023 Financial Results
November 09, 2023 07:00 ET
|
OncoCyte Corporation
-Launching First Products in 1H 2024- -Conference Call on Thursday, November 9, 2023 at 5:00 a.m. PT / 8:00 a.m. ET- IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq:...
Oncocyte to Announce Third Quarter 2023 Financial Results
November 03, 2023 08:30 ET
|
OncoCyte Corporation
IRVINE, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that the company will host a conference call and webcast on...
VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients
July 25, 2023 09:08 ET
|
Oncocyte Corporation
- Blood-based test differentiates between ABMR and IgAN, enabling faster and more effective treatment- Improved utility over standard of care tests- Paper published in peer-reviewed journal IRVINE,...
Oncocyte Announces 1-For-20 Reverse Stock Split
July 24, 2023 13:35 ET
|
Oncocyte Corporation
IRVINE, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX) (the “Company”), a precision diagnostics company, announced today that the Company will implement a 1-for-20...